의료진소개
혈액내과 김유진 조교수
전문진료분야
급성백혈병, 만성골수성백혈병, 조혈모세포이식, 골수이형성증, 재생불량성 빈혈, 혈우병, 빈혈, 백혈구질환, 혈소판질환, 응고질환, 각종 혈액질환
| 요일 | 월 | 화 | 수 | 목 | 금 |
|---|---|---|---|---|---|
| 오전 | 특수클리닉1 | 진료 | 진료 | ||
| 오후 | 진료 |
상세정보
학력
- 전북대학교 의학전문대학원 의학과 석사 졸업 (2012년)
- 성균관대학교 의과대학 박사 졸업 (2021년)
경력
- 서울삼성병원 인턴 (2012년 03월 – 2013년 02월)
- 서울삼성병원 내과 전공의 (2013년 03월 – 2017년 02월)
- 서울삼성병원 혈액종양내과 fellow (2016년 03월 – 2017년8월)
- 삼성창원병원 혈액종양내과 임상조교수 (2018년 9월-2021년 2월)
- 울산대학교 병원 혈액종양내과 임상조교수(2021년 3월 –2021년 8월)
- 울산대학교 병원 혈액종양내과 조교수(현재)
논문
- Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in advanced non-small cell lung cancer Eur J Immunology 2021 Jan 28. doi: 10.1002
- Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea; PLoS Med 17(6): e1003091.https://doi.org/10.1371/journal.pmed.1003091
- Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced non-small cell lung cancer in J Thorac Oncol. 2018 Oct 31. pii: S1556-0864(18)33383-5. doi: 10.1016
- Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor ;J Thorac Oncol. Volume 14, Issue 9, Pages 1608–1618
- Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib in Cancer Res Treat. 2018 Jun 13. doi: 10.4143/crt.2018.117.
- High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer; J Cancer. 2019; 10(14): 3172–3178.
- A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients; Cancer Research and Treatment > Volume 51(3); 2019, DOI: https://doi.org/10.4143/crt.2018.379
- Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial; J Gastric Cancer. 2018 Dec;18(4):348-355
- MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines; Oncotarget. 2017 Dec 1; 8(62): 105727–105734.
- Identification of FGFR3-TACC3 gene fusion in metastatic gastric cancer; Precis Future Med. 2017;1(4):168-172
- Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01): Nintedanib for Salivary Gland Cancer in CANCER 2017 Jun 1;123(11):1958-1964.
- The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial; J Gastric Cancer. 2016 Jun;16(2):105-10